Skip to content
value.today

Turn Therapeutics Inc.

TTRX
No market cap data
Compare
World rank
—
no current market cap
Revenue
—
For year ending December-2025
Net income
$-3 M
SEC filing
Employees
—

Turn Therapeutics Inc. in brief

Turn Therapeutics Inc. is a listed company in the Biotechnology industry, based in Westlake Village, California, USA. Its shares trade under the symbol TTRX (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Turn Therapeutics Inc.

Turn Therapeutics is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Our lead program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula.

GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema. We intend to conduct an interim assessment at approximately 50% trial completion. Topline results are expected mid-2026.

From the company's annual report filed with the US SEC: read the report

Turn Therapeutics Inc. timeline

3 events, 2024–2025
  1. 2024
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2025
  4. ✎
    Renamed Turn Therapeutics Inc.
    Formerly Global Health Solutions, Inc.
  5. 🔔
    Initial public offering
    Final prospectus filed with the SEC on 8 October 2025; shares registered for exchange trading on 29 September 2025.

Events of Turn Therapeutics Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

Not enough history yet.

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2024: revenue —, net income $-2M—FY24Fiscal year ending Dec 2025: revenue —, net income $-3M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-6M$-3M—
Dec 2024——$-2M$-2M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-3M——$-0.12—
Dec 2024$-1M——$-0.07—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Sep 2024: revenue —, net income $-1M—Sep ’24Three months to Mar 2025: revenue —, net income $-0M—Mar ’25Three months to Jun 2025: revenue —, net income $-1M—Jun ’25Three months to Sep 2025: revenue —, net income $-2M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $0M—Dec ’25Three months to Mar 2026: revenue —, net income $-1M—Mar ’26Three months to Jun 2026: revenue —, net income $-6M—Jun ’26Three months to Sep 2026: revenue —, net income $-6M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-6M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Turn Therapeutics Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-6 M
Net income
$-3 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$12 M
Total liabilities
$7 M
Total equity
$5 M

As of December-2025

Top 43 institutional investors in Turn Therapeutics Inc.#

As of Sep 30, 2026
43 institutions held 2.3 M shares (about 7.6% of the shares outstanding) on Sep 30, 2026. The ten largest hold 6.2%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Turn Therapeutics Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Vanguard Capital Management LLC423,893+349,592 (+470.51%)1.39%$6 MNov 13, 2026
2BlackRock, Inc.259,028+220,437 (+571.21%)0.85%$4 MNov 13, 2026
3SteelPeak Wealth, LLC251,275+1,819 (+0.73%)0.82%$4 MOct 16, 2026
4Ieq Capital, LLC227,3960 (0.00%)0.74%$3 MNov 10, 2026
5Millennium Management LLC167,802+107,251 (+177.13%)0.55%$2 MNov 16, 2026
6Geode Capital Management, LLC158,631+141,489 (+825.39%)0.52%$2 MNov 6, 2026
7Morgan Stanley139,674+128,327 (+1130.93%)0.46%$2 MNov 13, 2026
8DDFG, Inc111,379+3,550 (+3.29%)0.36%$2 MOct 15, 2026
9Susquehanna International Group, LLP94,076New0.31%$1 MNov 16, 2026
10HRT Financial LP57,450New0.19%$1 MNov 13, 2026
11Vanguard Fiduciary Trust Co36,048+23,568 (+188.85%)0.12%$1 MNov 13, 2026
12Aaron Wealth Advisors LLC32,5640 (0.00%)0.11%$0 MOct 13, 2026
13Northern Trust Corp30,762New0.10%$0 MNov 16, 2026
14Tamar Securities, LLC30,0000 (0.00%)0.10%$0 MNov 3, 2026
15Goldman Sachs Group Inc27,510New0.09%$0 MNov 16, 2026
16Bridgewater Advisors Inc.25,326-2,000 (-7.32%)0.08%$0 MNov 16, 2026
17HighTower Advisors, LLC24,279+4,595 (+23.34%)0.08%$0 MNov 10, 2026
18Brown Brothers Harriman & Co23,6880 (0.00%)0.08%$0 MNov 13, 2026
19Charles Schwab Investment Management Inc16,310New0.05%$0 MNov 16, 2026
20Jefferies Financial Group Inc.16,3000 (0.00%)0.05%$0 MNov 5, 2026
21LPL Financial LLC16,100+5,800 (+56.31%)0.05%$0 MNov 6, 2026
22McCarthy Asset Management, Inc.15,0180 (0.00%)0.05%$0 MOct 20, 2026
23Jump Financial, LLC14,944New0.05%$0 MNov 13, 2026
24Bank Of America Corp /de/14,1240 (0.00%)0.05%$0 MNov 16, 2026
25Barclays PLC13,748New0.04%$0 MNov 6, 2026
Show all 43: investors 26 to 43
Institutional investors 26 to 43 in Turn Therapeutics Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26ExodusPoint Capital Management, LP12,098New0.04%$0 MNov 16, 2026
27Schonfeld Strategic Advisors LLC11,214New0.04%$0 MNov 16, 2026
28Jane Street Group, LLC11,131New0.04%$0 MNov 12, 2026
29Qube Research & Technologies Ltd10,941New0.04%$0 MNov 13, 2026
30Composition Wealth, LLC10,000-6,000 (-37.50%)0.03%$0 MNov 10, 2026
31Cannon Financial Strategists, Inc.10,0000 (0.00%)0.03%$0 MOct 19, 2026
32Vanguard Global Advisers, LLC6,383New0.02%$0 MNov 13, 2026
33Aster Capital Management (DIFC) Ltd5,235New0.02%$0 MNov 12, 2026
34Citigroup Inc4,723New0.02%$0 MNov 4, 2026
35TD Waterhouse Canada Inc.3,059New0.01%$0 MOct 16, 2026
36Tower Research Capital LLC (TRC)2,671New0.01%$0 MNov 16, 2026
37UBS Group AG2,627+364 (+16.08%)0.01%$0 MNov 10, 2026
38Blue Trust, Inc.1,1220 (0.00%)0.00%$0 MOct 15, 2026
39Wells Fargo & Company/mn1,0000 (0.00%)0.00%$0 MNov 16, 2026
40Royal Bank Of Canada408-27,842 (-98.56%)0.00%$0 MNov 16, 2026
41Pflug Koory, LLC1700 (0.00%)0.00%$0 MOct 26, 2026
42Caitong International Asset Management Co., Ltd15-16 (-51.61%)0.00%$0 MOct 29, 2026
43Parkside Financial Bank & Trust10New0.00%$0 MOct 27, 2026

Mutual funds holding Turn Therapeutics Inc.#

7 funds hold shares worth $1 M (about 0.4% of the company). Since their previous reports 5 added shares and 2 sold, buying $0 M net.
Mutual funds holding Turn Therapeutics Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.62,749$0 M0.21%<0.01%+85%Jun 30, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors36,232$0 M0.12%0.02%newJun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC17,142$0 M0.06%<0.01%no changeMay 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.9,897$0 M0.03%<0.01%−36%Jun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC2,359$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.1,244$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.129$0 M<0.01%<0.01%newJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 7 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Turn Therapeutics Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$109 K
5 purchases, 2 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$109 K
open market only
Insiders on file
9
since
$191 K$0Oct 2025: bought $191 K (3 trades), sold $0 (0 trades)Oct 25Nov 2025: bought $109 K (5 trades), sold $0 (0 trades)NovDec 2025: bought $9 K (1 trades), sold $0 (0 trades)Dec
Bought (open market)Sold (open market)Hover a month for the totals
Turn Therapeutics Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Bradley Evan BurnamChief Executive Officer, Director, 10% ownerGiftindirect-300,000——15.42 MForm 4
filed Bradley Evan BurnamChief Executive Officer, Director, 10% ownerGiftindirect+300,000——300,000Form 4
filed Bradley Evan BurnamChief Executive Officer, Director, 10% ownerGiftindirect-300,000——15.12 MForm 4
filed Bradley Evan BurnamChief Executive Officer, Director, 10% ownerGiftindirect+300,000——300,000Form 4
filed BEB Holdings, LLC10% ownerGiftindirect-300,000——15.72 MForm 4
filed Arthur F. GoldenDirectorGift+300,000——360,602Form 4
filed Martin William DewhurstDirectorGrant or award+21,882——21,882Form 4
filed Zuraiz ChaudharySee RemarksBuy+2,500$3.500$9 K12,500Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Turn Therapeutics Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
530,526
1.8% of shares · 5.87 days to cover
Shares sold short, last 24 reportsAll stocks →

IPO: priced at $11.65, raising $208.2M · IPO calendar

Trading halts

  • 2025-10-24 18:41 UTC, code LUDP, resumed 18:46 UTC
  • 2025-10-09 14:23 UTC, code LUDP, resumed 14:28 UTC
  • 2025-10-09 13:52 UTC, code LUDP, resumed 13:57 UTC
  • 2025-10-09 13:42 UTC, code LUDP, resumed 13:47 UTC
  • 2025-10-08 15:53 UTC, code LUDP, resumed 15:58 UTC

Fails to deliver

  • : 116 shares at $10.61
  • : 116 shares at $10.28
  • : 3,200 shares at $10.47
  • : 5,157 shares at $11.39
  • : 88 shares at $14.39

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Turn Therapeutics Inc. scorecard#

Passes 0 of the 5 checks that could be worked out. Fiscal year 2025.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth0 of 1
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-0.12 vs -0.07Diluted EPS -0.12 in fiscal 2025 against -0.07 the year before (report's currency).
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 2
    • ✗Profitable in the newest year-$3 MNet income -$3 M in fiscal 2025.
    • –Profitable in each of the last five yearsFive years of net income are not on file.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-141.5%-141.5% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health0 of 1
    • ✗Short-term assets cover short-term liabilities0.9×Current ratio 0.87 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • –Cash from operations positive in each of the last three yearsThree years of operating cash flow are not on file.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year4.0%Diluted shares up 4.0% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Turn Therapeutics Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Turn Therapeutics Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024
Income statement
Research and development266246
General and administrative5,5931,551
Operating expenses5,8591,797
Operating income−5,859−1,797
Interest and finance income3029
Other non-operating income (expense)2,66529
Net income attributable to shareholders−3,194−1,768
Earnings per share, basic-0.12-0.07
Earnings per share, diluted-0.12-0.07
Shares, weighted average (basic)2827
Shares, weighted average (diluted)2827
Balance sheet
Cash and cash equivalents4,028498
Other current assets120225
Current assets5,1961,098
Right-of-use (leased) assets79120
Other intangible assets922822
Total assets12,1622,049
Current liabilities6,003708
Lease liabilities (non-current)3480
Total liabilities7,4762,226
Retained earnings−22,390−19,196
Shareholders' equity4,687−177
Total liabilities and equity12,1622,049
Shares outstanding2927
Cash-flow statement
Depreciation and amortization5347
Share-based compensation419353
Cash from operating activities−2,563−1,361
Intangible assets bought−153−99
Cash from investing activities−153−99
Shares issued6,9191,152
Cash from financing activities6,9191,152
Report10-K10-K

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at Turn Therapeutics Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 2 · Material agreement 3 · New debt 1 · Unregistered share sale 2 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Results announced 5

Turn Therapeutics Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Unregistered share sale8-K
Results announced8-K
Results announced8-K
Results announced8-K
Material agreementNew debtUnregistered share sale8-K
Directors and officers8-K
Results announced8-K
Material agreement8-K
Directors and officersMaterial agreementShareholder rights changedBylaws or fiscal year changed8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 9, 2026

Acquisitions and funding#

Private share sales · funding history

Private share sales of Turn Therapeutics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2026$2 MPrivate placement after listingUnder $2 million8equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Lobbying by Turn Therapeutics Inc.#

$0 spent on lobbying the US Congress and federal agencies in 2021.

Lobbying, 2021
$0
#1,466 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
2
in 2021
2026 so far
—

Lobbying firms hired in 2021

CONNECT STRATEGY LLC · Turnberry Solutions, LLC

Turn Therapeutics Inc.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2021$0—3
2020$10 K—3

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Turn Therapeutics”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Turn Therapeutics Inc.🇺🇸————
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 16, 2026

Figures from SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Turn Therapeutics Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Turn Therapeutics Inc.'s ranking on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Turn Therapeutics Inc.? Suggest a correction